Clinical trials: Chronic Kidney Disease Stage 4
Chronic Kidney Disease
Effect of a Phosphate Modified Diet on Phosphate Balance and Phosphate Metabolism in Predialysis Patients Stage 3-4
Patients with chronic kidney disease struggle to eliminate phosphate as the renal function deteriorates, which results in accumulation of phosphate in the body.
- Trial name
- NCT02073136
- Testing
- Diet with phosphate containing additives, Diet without phosphate containing additives
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- University of Copenhagen
Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 5
The Agenda-Setting for Kidney Disease Trial
The goal of this clinical trial is to learn if a tool with a list of discussion topics, called a structured clinical visit agenda-setting intervention (SAS), works for people with advanced chronic kidney disease (CKD) who receive…
- Trial name
- ASK (NCT07024953)
- Testing
- Chronic Kidney Disease Structured Agenda-Setting Tool
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 3B
Fluorescein Angiography in Patients With Diabetes and Chronic Kidney Disease
Our study hypothesizes that fluorescein exposure in diabetic patients with advanced chronic kidney disease results in deterioration of kidney function.
- Conditions
- Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 3B, Chronic Kidney Disease Stage 5, Diabetes Mellitus
- Trial name
- Fluo-AKI (NCT06760650)
- Testing
- Fluorescein angiography
- Where
- Lebanon
- Volunteers
- 35 people
- Sponsor
- Saint-Joseph University
Anaemia
Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia
This study is intended to evaluate the dose-response relationship of GSK1278863 over the first 4 weeks of treatment and evaluate the safety and efficacy of GSK1278863 over 24 weeks to maintain hemoglobin (Hgb) level in…
- Trial name
- NCT01977482
- Testing
- GSK1278863, rhEPO
- Where
- 107 sites in United States, Australia and 14 more
- Volunteers
- 216 people
- Sponsor
- GlaxoSmithKline
Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme
This study was designed to determine appropriate treatment with Fabrazyme at a biweekly dose of either 1 mg/kg or 3 mg/kg in a population of patients with severe renal disease burden.
- Trial name
- NCT00837824
- Testing
- Fabrazyme (agalsidase beta)
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Genzyme, a Sanofi Company
Chronic Kidney Disease
Metabolic Effects of Paricalcitol
The purpose of this study is to determine if treatment with paricalcitol, an active form of vitamin D, has beneficial effects on metabolic abnormalities in people with stage 3-4 Chronic Kidney Disease (CKD).
- Trial name
- NCT01003275
- Testing
- Paricalcitol
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Washington
Chronic Renal Failure
Change From Baseline to Chronic Kidney Disease Patient Before and After Administration Drug
Chronic renal failure is a syndrome that renal function is decreased, and the patient number is increasing. In addition, patients on dialysis have also increased.
- Trial name
- NCT02378194
- Testing
- HD-003 (800mg/day), HD-003 (1600mg/day)
- Volunteers
- 62 people
- Sponsor
- Hyundai Pharmaceutical Co., LTD.
Cancer
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
RATIONALE: Vaccines may help the body build an effective immune response to kill cytomegalovirus infections. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients who have…
- Trial name
- NCT00509691
- Testing
- cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Louisville
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
- Trial name
- NCT01704079
- Testing
- CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- OPKO IP Holdings II, Inc.
End Stage Renal Disease, Inflammation
Evaluation of Biocompatibility and Performances of 4 Dialyzers in Different Mode Treatments
Prospective multicenter randomized cross-over study Number of patients : 32 (8 patients per group) Obtain objectives data to advise each hemodialyzer according to dialysis treatment and patient profile.
- Trial name
- BIOMODAL (NCT03262272)
- Testing
- VIE A Hemodialyzer, Rexsys 27H hemodialyzer, Leoceed 21HX hemodialyzer
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Hemotech
Chronic Kidney Diseases
Dapagliflozin in Non-diabetic Stage IV CKD
This is a phase 2b, prospective, randomized, cross-over, double-blind, placebo-controlled trial primarily aimed at assessing whether the SGLT2 inhibitor dapagliflozin ameliorates hyperfiltration and reduces proteinuria as…
- Trial name
- ADAPT (NCT04794517)
- Testing
- Dapagliflozin 10Mg Tab
- Where
- Italy
- Volunteers
- 32 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Chronic Kidney Disease, Anemia
Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis
The primary objective of the study is to evaluate the safety, tolerability, and pharmacodynamic effects of different oral doses of roxadustat administered 2 times a week (BIW) or 3 times a week (TIW) for up to 4 weeks to…
- Trial name
- NCT00761657
- Testing
- Roxadustat
- Where
- 34 sites in United States
- Volunteers
- 117 people
- Sponsor
- Kyntra Bio
Chronic Renal Insufficiency, Proteinuria
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
A randomized clinical trial to determine if vitamin D repletion in CKD (Chronic Kidney Disease) patients with low vitamin D levels will decrease proteinuria, a marker of kidney damage.
- Trial name
- NCT01029002
- Testing
- Vitamin D
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Albert Einstein College of Medicine
CKD Stage 4, CKD Stage 5
Frailty, Cognitive Function and Health-related Quality of Life in Older Adults With Advanced Chronic Kidney Disease.
This observational study explores the impact of cognitive impairment and frailty in older adults with advanced chronic kidney disease ].
- Conditions
- CKD Stage 4, CKD Stage 5, Frailty, Cognitive Impairment
- Trial name
- NCT05705011
- Where
- Romania
- Volunteers
- 240 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Insulin Resistance, Diabetes
Insulin Resistance And End Stage Renal Disease: The Role Of Retinol Binding Protein 4
The purpose of this study is to determine whether Retinol binding protein 4 has a role in insulin resistance development in patients suffering from end stage renal disease on hemodialysis.
- Conditions
- Insulin Resistance, Diabetes, End Stage Renal Disease
- Trial name
- NCT00910130
- Where
- Italy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Chronic Kidney Disease
Ergocalciferol in Chronic Kidney Disease
To examine the effect of ergocalciferol treatment on 25-hydroxyvitamin D and PTH levels in patients with CKD stage 3 and 4
- Trial name
- NCT00411294
- Where
- United States
- Sponsor
- Saint Louis VA Medical Center
END STAGE RENAL DISEASE
ESTEROID WITHDRAWAL STUDY, SAFETY AND EFFICACY IN RENAL TRANPLANTATION
BACKGROUND: Non-steroid maintenance immunosuppression after transplantation can improve long-term lipid and hemodynamic profiles without severe acute rejection (AR) events that alter graft function or survival.
- Trial name
- ESWMEX001 (NCT02328222)
- Testing
- ESW group
- Where
- Mexico
- Volunteers
- 71 people
- Sponsor
- Unidad de Investigacion Medica en Enfermedades Renales
Chronic Kidney Disease, Obesity
Weight Loss Interventions in Obese Patients With Stages 3-4 Chronic Kidney Disease: a Randomised Controlled Trial
Weight loss surgery is the most effective weight loss treatment available, but the direct effect on chronic kidney disease is less widely understood.
- Trial name
- NCT01053130
- Testing
- laparoscopic sleeve gastrectomy, weight management program
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- King's College Hospital NHS Trust
ESRD, CKD Stage 4, CKD Stage 5
Canagliflozin in Advanced Renal Disease With MRI Endpoints
This is a phase II, proof of concept, placebo-controlled, randomized clinical trial, assessing the effect of canagliflozin on cardiac structure and function in patients with advanced renal disease, including those on maintenance…
- Trial name
- CARe-MRI (NCT06182839)
- Testing
- Canagliflozin 300Mg Tab
- Where
- Canada
- Volunteers
- 92 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
CKD Stage 3b, CKD Stage 4
The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4
The aim of this study is to investigate effects of sevelamer carbonate on reducing TMAO in stage 3b-4 CKD (pre-dialysis) patients.
- Trial name
- NCT03596749
- Testing
- Sevelamer Carbonate
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fan Fan Hou